Experimental eye injections aim to halt rare genetic blindness

NCT ID NCT06852963

Summary

This study is testing the safety and effectiveness of repeat injections of an experimental drug, VP-001, into the eye. It is for adults with a rare, inherited form of vision loss called PRPF31 mutation-associated retinal dystrophy. The goal is to see if the injections can help control the disease and preserve or improve vision over time.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RETINAL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Bascom Palmer Eye Institute - University of Miami

    RECRUITING

    Miami, Florida, 33136, United States

    Contact Email: •••••@•••••

    Contact

  • Baylor College of Medicine

    RECRUITING

    Houston, Texas, 77030, United States

    Contact

    Contact Email: •••••@•••••

  • Casey Eye Institute - OHSU

    RECRUITING

    Portland, Oregon, 97239, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Kellogg Eye Center - University of Michigan

    RECRUITING

    Ann Arbor, Michigan, 48105, United States

    Contact Email: •••••@•••••

    Contact

  • Retina Foundation of the Southwest

    RECRUITING

    Dallas, Texas, 75231, United States

    Contact

    Contact Email: •••••@•••••

  • University of Florida College of Medicine

    RECRUITING

    Jacksonville, Florida, 32209, United States

    Contact Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.